

Title (en)
NOVEL INDOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Title (de)
NEUARTIGE INDOLDERIVATE, HERSTELLUNGSVERFAHREN DAFÜR UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN DAMIT

Title (fr)
DERIVES INDOLIQUES, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT

Publication
EP 2079689 A2 20090722 (FR)

Application
EP 07858468 A 20071017

Priority
• FR 2007001708 W 20071017
• FR 0609113 A 20061018

Abstract (en)
[origin: FR2907451A1] Indole derivatives (I), their enantiomers, diastereomers and their acid/base addition salts are new. Indole derivatives of formula (I), their enantiomers, diastereomers and their acid/base addition salts are new. R 11-6C alkyl, 3-8C cycloalkyl or 3-8C cycloalkyl-1-6C alkyl, preferably alkyl; NR 2R 35-8 membered heterocycle, preferably piperidiny; and n : 2-6, preferably 2. An independent claim is included for the preparation of (I). [Image] ACTIVITY : Hypnotic; Tranquilizer; Antidepressant; Cardiovascular-Gen; Gastrointestinal-Gen; Neuroleptic; Anorectic; Anticonvulsant; Antidiabetic; Antiparkinsonian; Nootropic; Antimigraine; Neuroprotective; Endocrine-Gen; Contraceptive; Immunomodulator; Cytostatic. MECHANISM OF ACTION : Melatonin receptor binder. The affinity of (I) to bind with melatonin receptors MT1 and MT2 was tested using 2-[1> 2> 5>I]-iodomelatonin as reference radioligand. The results showed that (I) exhibited an inhibition constant value of less than 1 mu M.

IPC 8 full level
A61K 31/4045 (2006.01); **C07D 209/32** (2006.01)

CPC (source: EP KR US)
A61K 31/4045 (2013.01 - KR); **A61P 1/00** (2017.12 - EP); **A61P 1/14** (2017.12 - EP); **A61P 3/04** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 15/00** (2017.12 - EP); **A61P 15/10** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/06** (2017.12 - EP); **A61P 25/08** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 25/18** (2017.12 - EP); **A61P 25/20** (2017.12 - EP); **A61P 25/22** (2017.12 - EP); **A61P 25/24** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 209/14** (2013.01 - EP KR US); **C07D 209/32** (2013.01 - KR)

Citation (search report)
See references of WO 2008049997A2

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

Designated extension state (EPC)
AL BA HR MK RS

DOCDB simple family (publication)
FR 2907451 A1 20080425; **FR 2907451 B1 20081212**; AR 063328 A1 20090121; AU 2007310770 A1 20080502; BR PI0717528 A2 20131022; CA 2666522 A1 20080502; CN 101522616 A 20090902; EA 200900481 A1 20091030; EP 2079689 A2 20090722; GE P20115240 B 20110610; JP 2010506890 A 20100304; KR 20090084874 A 20090805; MA 30797 B1 20091001; MX 2009004006 A 20090428; NO 20091779 L 20090506; UA 91645 C2 20100810; US 2010204276 A1 20100812; WO 2008049997 A2 20080502; WO 2008049997 A3 20080912; WO 2008049997 A8 20090522; ZA 200902414 B 20100728

DOCDB simple family (application)
FR 0609113 A 20061018; AR P070104591 A 20071017; AU 2007310770 A 20071017; BR PI0717528 A 20071017; CA 2666522 A 20071017; CN 200780037231 A 20071017; EA 200900481 A 20071017; EP 07858468 A 20071017; FR 2007001708 W 20071017; GE AP2007011251 A 20071017; JP 2009532844 A 20071017; KR 20097010133 A 20071017; MA 31793 A 20090416; MX 2009004006 A 20071017; NO 20091779 A 20090506; UA A200904632 A 20071017; US 31180507 A 20071017; ZA 200902414 A 20071017